Neurosterix NTX-253 Phase 1 Schizophrenia Trial On Track for Q2 2026 Completion

Key Takeaways

• Neurosterix remains on schedule to complete Phase 1 clinical study of NTX-253 for schizophrenia by Q2 2026
• NTX-253 is a novel oral positive allosteric modulator targeting neurological disorders with potential for improved patient outcomes
• Successful Phase 1 completion would advance NTX-253 toward Phase 2 trials and bring new schizophrenia treatment options closer to patients

---

Geneva, Switzerland - Neurosterix, a spin-out company from Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), announced it remains on track to complete its Phase 1 clinical study of NTX-253 for schizophrenia treatment in the second quarter of 2026.

About NTX-253 and Its Mechanism

NTX-253 represents an investigational potent, selective, and orally available positive allosteric modulator designed specifically for neurological disorders. This novel approach differs from traditional schizophrenia medications by targeting allosteric sites on neurotransmitter receptors, potentially offering improved efficacy with reduced side effects.

Addex Therapeutics, the parent company, specializes in developing small molecule allosteric modulators for neurological conditions, bringing significant expertise to Neurosterix’s development program.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Development Timeline

The Phase 1 study focuses on establishing NTX-253’s safety profile, determining optimal dosing ranges, and evaluating preliminary efficacy signals in patients with schizophrenia. Completion by Q2 2026 would position Neurosterix to advance into Phase 2 trials, where the drug’s therapeutic potential will undergo more comprehensive evaluation.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Patient Implications

Schizophrenia affects approximately 1.1% of adults worldwide, with current treatments often causing significant side effects including weight gain, metabolic changes, and movement disorders. NTX-253’s allosteric modulation approach could potentially address these limitations while maintaining or improving therapeutic efficacy.

The successful progression of NTX-253 through Phase 1 trials represents a critical milestone for both Neurosterix and patients seeking better treatment options. If proven safe and effective, this novel mechanism could expand the limited arsenal of schizophrenia medications currently available.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Next Steps

Following Phase 1 completion, Neurosterix will analyze safety and efficacy data to design Phase 2 protocols. The company’s progress will be closely monitored by investors and the medical community as it advances this potentially transformative treatment approach.

---

Frequently Asked Questions

What makes NTX-253 different from existing schizophrenia treatments?

NTX-253 is a positive allosteric modulator that targets specific receptor sites differently than traditional antipsychotics, potentially offering improved efficacy with fewer side effects like weight gain and metabolic issues.

When will NTX-253 be available to patients?

NTX-253 is currently in Phase 1 trials, expected to complete in Q2 2026. If successful, it would need to complete Phase 2 and Phase 3 trials before potential FDA approval, likely taking several more years.

What happens if the Phase 1 trial is successful?

Successful Phase 1 completion would allow Neurosterix to advance NTX-253 into Phase 2 trials, where the drug’s effectiveness will be tested in larger patient groups with more comprehensive safety monitoring.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
• MariTide Phase 2 obesity data show up to 20% weight loss at one year